000282937 001__ 282937
000282937 005__ 20251218141747.0
000282937 037__ $$aDZNE-2025-01398
000282937 1001_ $$0P:(DE-2719)2810938$$aMüller, Stephan A$$b0$$udzne
000282937 245__ $$aDataset: Secretome and lysate proteomics of primary murine neurons with inactive BACE1 (Project PXD065011)
000282937 260__ $$bPRoteomics IDEntifications Database$$c2025
000282937 3367_ $$2BibTeX$$aMISC
000282937 3367_ $$0PUB:(DE-HGF)32$$2PUB:(DE-HGF)$$aDataset$$bdataset$$mdataset$$s1766063848_31263
000282937 3367_ $$026$$2EndNote$$aChart or Table
000282937 3367_ $$2DataCite$$aDataset
000282937 3367_ $$2ORCID$$aDATA_SET
000282937 3367_ $$2DINI$$aResearchData
000282937 520__ $$aThe β-secretase BACE1 has become a prime target in Alzheimer’s disease (AD) therapy, because it drives the production of pathogenic amyloid β peptides. However, clinical trials with BACE1-targeting drugs were halted due to adverse effects on cognitive performance. We propose here that cognitive impairment by BACE1 inhibitors may be a corollary of a higher function of BACE1 related to proper sleep regulation. To address non-enzymatic effects of BACE1 on ion channels likely involved in the sleep–wake cycle, we analyzed sleep patterns in both BACE1-KO mice and a newly generated transgenic line expressing a proteolysis-deficient BACE1 variant (BACE1-KI). To investigate changes in the cellular proteome as well as the secretome, primary neurons were metabolically labeled with ManNAz and the secretome was anlyzed using the hiSPECS method. The results showed areduction of several BACE1 substrates in the secretome (i.e. SEZ6, APLP1) as well as an accumulation of some BACE1 substrates in the lysate (i.e. APLP1, SEZ6, CNTN2).
000282937 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000282937 7001_ $$0P:(DE-2719)2181459$$aLichtenthaler, Stefan$$b1$$udzne
000282937 8564_ $$uhttps://wwwdev.ebi.ac.uk/pride/archive/projects/PXD065011
000282937 909CO $$ooai:pub.dzne.de:282937$$pVDB
000282937 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810938$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000282937 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2181459$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000282937 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000282937 9141_ $$y2025
000282937 9201_ $$0I:(DE-2719)1110006$$kAG Lichtenthaler$$lNeuroproteomics$$x0
000282937 980__ $$adataset
000282937 980__ $$aVDB
000282937 980__ $$aI:(DE-2719)1110006
000282937 980__ $$aUNRESTRICTED